Kailera Therapeutics Launches with $400 Million Series A Financing

Kailera Therapeutics, Inc. has launched as a clinical-stage biopharmaceutical company, announcing a $400 million Series A financing round. The funding was co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Capital. This capital infusion is intended to advance the company's portfolio of therapies for obesity and related metabolic conditions.

The company acquired global development and commercialization rights for four metabolic disease assets from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Kailera's lead program is KAI-9531, an injectable GLP-1/GIP receptor dual agonist that has shown positive results in Phase 2 trials in China for obesity and type 2 diabetes. The pipeline also includes KAI-7535, an oral small molecule GLP-1 receptor agonist, and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.

Ron Renaud has been appointed Chief Executive Officer. He brings over 25 years of biopharmaceutical leadership experience, having previously held executive roles at Cerevel Therapeutics and Translate Bio. The company has also announced key leadership appointments and the appointment of John F. Milligan as Chair of the Board. Milligan is a veteran executive with prior experience as CEO of Gilead Sciences.

The launch and significant funding underscore the growing demand for innovative obesity treatments. Kailera aims to develop differentiated, next-generation therapies targeting chronic weight management, with the goal of improving patient quality of life and overall health outcomes.